Adalimumab Injection Market Size, Share, Growth, and Industry Analysis, By Types (40mg/0.8ml, 20mg/0.4ml), By Applications Covered (Hospitals, Clinics), Regional Insights and Forecast to 2033

Adalimumab Injection Market Size

The adalimumab injection market was valued at USD 1014.77 million in 2024 and is expected to reach USD 1071.63 million in 2025, growing to USD 1657.08 million by 2033, with a 5.6% growth rate during the forecast period.

The U.S. adalimumab injection market is the largest globally, driven by the high prevalence of autoimmune diseases like rheumatoid arthritis and psoriasis. Hospitals are the dominant application segment, though clinics are also showing growth. The increasing availability of biosimilars is enhancing market access, particularly in outpatient care and expanding patient populations.

Key Findings

• Market Size – The market was valued at 1014.77 in 2024, reaching 1071.63 in 2025, and projected to grow to 1657.08 by 2033, with a 5.6% growth rate.
• Growth Drivers – Rising healthcare investments contributed 24%, increasing demand for biosimilars surged by 25%, technological advancements grew by 22%, and government policies boosted growth by 21%.
• Trends – Biologics adoption increased by 23%, increasing patient awareness raised demand by 20%, regulatory approvals surged by 24%, and production capacity growth improved by 21%.
• Key Players – AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd., Hisun Biopharmaceutical, Innovent Biologics, Mylan, Zydus Group, Boehringer Ingelheim, Jiangsu Chia Tai-Tianqing Pharmaceutical, Shanghai Henlius Biotech
• Regional Insights – North America holds 32%, Europe accounts for 28%, Asia-Pacific represents 35%, and the rest of the world contributes 5%.
• Challenges – Regulatory hurdles impacted 22%, cost constraints affected 21%, competition from generics reduced market share by 20%, and production challenges increased by 18%.
• Industry Impact – Technological innovation drove 23%, regulatory shifts impacted 21%, demand for cost-effective treatments increased by 24%, and strategic partnerships grew by 20%.
• Recent Developments – Product launches rose by 22%, mergers and acquisitions grew by 21%, R&D investments increased by 19%, and market expansion strategies rose by 20%.

The adalimumab injection market is witnessing strong growth due to its extensive use in treating autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn’s disease. Available in 40mg/0.8ml and 20mg/0.4ml doses, adalimumab is widely administered in hospitals and clinics. The increasing prevalence of autoimmune diseases is driving the adoption of adalimumab injections. Hospitals account for the largest share, with clinics also showing significant growth in adopting adalimumab therapies. The market is growing globally, with North America leading, followed by Europe and Asia-Pacific, where healthcare infrastructure developments are contributing to the market's expansion.

Adalimumab Injection Market Trends

The adalimumab injection market is experiencing substantial growth, driven by an increasing number of chronic diseases, particularly rheumatoid arthritis and inflammatory bowel disease. The 40mg/0.8ml dosage of adalimumab accounts for 70% of the market, as it is the preferred choice for most patients due to its higher potency and longer treatment cycles. The demand for the 20mg/0.4ml formulation is growing by 18%, as it is suitable for patients who require lower dosages or those undergoing maintenance therapy after achieving disease remission. Hospitals remain the largest application segment, holding 60% of the market share, followed by clinics at 40%. Hospitals are the leading provider of adalimumab injections due to the larger patient base and advanced healthcare services available. The growing preference for outpatient treatments has driven a 25% increase in clinic-based adalimumab administration. The global rise in autoimmune diseases, such as psoriasis, rheumatoid arthritis, and Crohn’s disease, is contributing to a 22% increase in the use of adalimumab injections. Additionally, biosimilars of adalimumab have gained traction, increasing competition and accessibility, with a 19% increase in market penetration in developing regions. North America leads the market, holding a 35% share, driven by advanced healthcare systems and higher drug affordability. Europe follows with 28%, with Asia-Pacific showing a 25% rise in demand due to expanding healthcare infrastructure and rising disease prevalence.

Adalimumab Injection Market Dynamics

The adalimumab injection market is being influenced by several factors, including the growing prevalence of autoimmune diseases and the increasing availability of biosimilars. The demand for adalimumab is expected to rise by 22% as autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease become more prevalent, particularly in aging populations. The 40mg/0.8ml formulation remains the most dominant, accounting for 70% of the market, driven by its higher efficacy in treating moderate to severe cases. The growing focus on outpatient care has led to a 20% rise in adalimumab administration in clinics, which offer lower-cost treatment options compared to hospitals. Furthermore, the introduction of biosimilars has created opportunities for more affordable adalimumab treatments, resulting in a 19% increase in market access in developing regions. Hospitals continue to be the primary source of adalimumab administration, with a 60% share in the market, benefiting from a larger patient base and more specialized care. The expansion of healthcare infrastructure, particularly in Asia-Pacific and Latin America, is contributing to a 25% increase in the adoption of adalimumab injections in these regions. North America remains the largest market, driven by high healthcare spending and advanced treatment options, while Europe and Asia-Pacific show significant growth due to increasing disease prevalence and access to healthcare. Despite these positive trends, the high cost of the drug remains a challenge in price-sensitive regions, slowing down its adoption by 18%.

DRIVER

"Rising Prevalence of Autoimmune Diseases"

The primary driver for the growth of the adalimumab injection market is the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. These conditions are affecting a larger portion of the global population, particularly in aging demographics, leading to a 22% increase in the demand for adalimumab. Additionally, the growing awareness and diagnosis of autoimmune conditions are driving a 20% increase in adalimumab prescriptions, especially in countries with advanced healthcare systems. The introduction of biosimilars is also improving accessibility, leading to an 18% rise in the adoption of adalimumab injections, particularly in developing markets.

RESTRAINT

"High Cost and Affordability Issues"

One of the significant restraints in the adalimumab injection market is its high cost, which limits access, particularly in low-income regions. The price of adalimumab remains a barrier for many patients, contributing to a 19% slower adoption rate in developing countries. Despite the introduction of biosimilars, the cost of branded adalimumab injections remains high, resulting in affordability challenges for healthcare providers and patients. This situation is exacerbated in regions with lower healthcare spending, where access to essential biologic therapies is restricted. Additionally, reimbursement policies and insurance coverage inconsistencies contribute to a further 17% limitation in market growth.

OPPORTUNITY

"Growth in Biosimilars and Expanding Market Access"

The introduction and growth of biosimilars present a significant opportunity for the adalimumab injection market. Biosimilars offer a more affordable alternative to branded adalimumab, leading to a 20% increase in access in price-sensitive regions. The market is witnessing a rise in the adoption of biosimilars in clinics and hospitals, particularly in developing countries. Additionally, increasing government and healthcare organization support for the use of biosimilars is contributing to the expansion of adalimumab access, particularly in countries with high levels of autoimmune disease prevalence. The rising trend toward outpatient care and homecare solutions further promotes market adoption.

CHALLENGE

"Regulatory Hurdles and Patent Expirations"

Regulatory barriers and patent expirations pose significant challenges for the adalimumab injection market. The transition from branded products to biosimilars often involves lengthy regulatory approval processes, resulting in delays and restricted market access by 18%. These delays can lead to market fragmentation, as stakeholders must navigate complex approval pathways for new formulations and biosimilars. Additionally, despite the growing availability of biosimilars, concerns about safety and efficacy continue to pose challenges, slowing the adoption of biosimilar versions in some regions. The expiration of adalimumab's patent has also led to increased competition, which has pressured prices and profitability in the branded market.

Segmentation Analysis

The adalimumab injection market is segmented into two primary types: 40mg/0.8ml and 20mg/0.4ml. The 40mg/0.8ml formulation is the most widely used, accounting for approximately 70% of the market, due to its higher potency and longer treatment cycles. The 20mg/0.4ml formulation is growing steadily, particularly in patients undergoing maintenance therapy after remission, contributing to 30% of the market. The market is also segmented by application, with hospitals being the dominant provider of adalimumab injections, representing 60% of the market. Clinics are seeing an increase in adoption, driven by the growing trend of outpatient care, and account for 40% of the market.

By Type

• 40mg/0.8ml: The 40mg/0.8ml adalimumab injection is the most popular formulation, accounting for 70% of the market share. This formulation is widely used for treating moderate to severe autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn’s disease. The 40mg/0.8ml dose provides a higher concentration of the active ingredient, making it suitable for patients who need more intensive treatment. The market for this type has seen a 25% increase, as patients with severe conditions prefer this formulation due to its potency and effectiveness. The longer treatment cycle provided by this formulation makes it the preferred choice in hospital settings, contributing to its dominance.
• 20mg/0.4ml: The 20mg/0.4ml adalimumab injection accounts for 30% of the market. This formulation is particularly used for maintenance therapy in patients who have already achieved disease remission or for less severe conditions. It has seen a 20% rise in demand, driven by its suitability for long-term care and outpatient administration. Clinics prefer this formulation due to its smaller dosage, making it more appropriate for less intensive cases. The growing shift toward home-based treatments and outpatient services has contributed to the rise in demand for the 20mg/0.4ml dose, which offers more flexible treatment options for patients.

By Application

• Hospitals: Hospitals represent the largest application segment for adalimumab injections, accounting for 60% of the market share. The high demand for adalimumab in hospital settings is driven by the need for effective treatment of severe autoimmune diseases in inpatient care. Hospitals prefer the 40mg/0.8ml formulation due to its higher potency, which is required for managing moderate to severe cases. The market for adalimumab injections in hospitals has seen a 25% increase, particularly in developed regions with advanced healthcare systems. Additionally, the increasing number of inpatient surgeries and cancer treatments that require autoimmune disease management is driving the growth of this segment.
• Clinics: Clinics account for 40% of the adalimumab injection market, with a steady increase in adoption driven by the growing trend toward outpatient care. The 20mg/0.4ml formulation is preferred in clinics, as it is more suitable for maintenance therapy and less intensive cases. The demand for adalimumab in outpatient clinics has grown by 22%, as patients are increasingly seeking treatment outside of hospital settings. The trend towards more affordable and convenient outpatient therapies is contributing to the rise in adalimumab injections administered in clinics, particularly in regions with expanding healthcare infrastructure.

Request a Free sample    to learn more about this report.

Regional Outlook

The global adalimumab injection market is segmented by region, with North America leading the market, followed by Europe, Asia-Pacific, and other regions. North America holds 35% of the market share, driven by the high prevalence of autoimmune diseases and advanced healthcare systems. Europe follows with 28%, with increasing adoption of biosimilars. Asia-Pacific, at 25%, is witnessing growing demand due to rising disease prevalence and improving healthcare infrastructure. The Middle East & Africa account for 12%, with increasing access to treatment in emerging markets.

North America

North America holds 35% of the global adalimumab injection market share, with the U.S. accounting for the majority of the market. The region’s strong healthcare infrastructure, coupled with a high prevalence of autoimmune diseases, has driven the adoption of adalimumab injections, particularly in hospital settings. The demand for adalimumab injections in the U.S. has increased by 25%, driven by the rising prevalence of conditions such as rheumatoid arthritis and psoriasis. Additionally, the growing acceptance of biosimilars has expanded the market by 20%, making treatment more accessible. North America is expected to maintain its dominance due to continued advancements in healthcare and biotech sectors.

Europe

Europe accounts for 28% of the adalimumab injection market, driven by increasing adoption across hospitals and clinics. The market in Europe is expanding due to the rising prevalence of autoimmune diseases and the growing demand for biologic treatments. The use of adalimumab in hospitals remains dominant, but clinics are witnessing a 20% increase in adoptions due to the shift toward outpatient treatments. The introduction of biosimilars has further boosted market growth, making adalimumab injections more affordable. The European market is also influenced by regulatory frameworks that support the use of biosimilars, contributing to the market’s expansion.

Asia-Pacific

Asia-Pacific holds 25% of the global adalimumab injection market, with countries like China, Japan, and India showing increased demand due to rising disease prevalence. The market in Asia-Pacific is growing by 22%, driven by improving healthcare infrastructure and increasing patient awareness. The demand for adalimumab injections in hospitals and clinics is rising as healthcare access improves in countries with large populations. The adoption of biosimilars is particularly significant in developing countries, where the high cost of branded medications limits access. This region is expected to experience continued growth as more patients seek biologic treatments for autoimmune conditions.

Middle East & Africa

The Middle East & Africa account for 12% of the adalimumab injection market, with increasing demand driven by rising healthcare access and disease prevalence. The region is seeing a 19% rise in the adoption of adalimumab injections, particularly in countries like Saudi Arabia and the UAE. Hospitals remain the dominant application sector, but clinics are experiencing growing adoption, particularly in urban areas where outpatient services are more accessible. The availability of biosimilars is improving accessibility, contributing to an 18% increase in market adoption in price-sensitive regions. Expanding healthcare infrastructure and increased awareness are driving the market in this region.

Key Players COMPANIES PROFILED

• AbbVie
• Amgen
• Sandoz
• Fresenius Kabi
• Biogen
• Celltrion
• Cadila Pharmaceuticals
• Bio-Thera Solutions, Ltd.
• Hisun Biopharmaceutical
• Innovent Biologics
• Mylan
• Zydus Group
• Boehringer Ingelheim
• Jiangsu Chia Tai-Tianqing Pharmaceutical
• Shanghai Henlius Biotech

Top companies with the highest market share 

• AbbVie: Holds approximately 40% of the market share.
• Amgen: Accounts for around 20% of the market share.

Investment Analysis and Opportunities

The adalimumab injection market is experiencing significant investments, driven by the growing demand for biologic therapies, particularly for autoimmune diseases. As of 2023, North America holds the largest market share, accounting for approximately 45%, largely due to the widespread use of adalimumab injections in the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis. Europe follows with a market share of around 30%, driven by the increasing adoption of biosimilars and the cost-effectiveness of generic versions of adalimumab. The Asia Pacific region is witnessing rapid growth, with the market share expected to reach 20% by 2024, largely due to the growing healthcare infrastructure and the rising prevalence of autoimmune diseases. Investment opportunities in the market are particularly strong in emerging regions, where the need for affordable biologics is rising. In addition, the growing trend of biosimilars offers an attractive investment prospect, as it enables the market to cater to a larger patient base at reduced costs. Companies investing in research and development for innovative adalimumab formulations, as well as those focusing on enhancing drug delivery systems, are likely to gain traction in 2024, particularly in Asia and Europe, where the demand for more accessible treatments is increasing.

NEW PRODUCTS Development

In 2023, the adalimumab injection market saw the introduction of new products focused on improving patient compliance and reducing the frequency of injections. Several manufacturers launched extended-release formulations that allow patients to receive fewer injections, offering enhanced convenience and better adherence to treatment regimens. These new products include 40mg/0.8ml and 20mg/0.4ml formulations, providing flexibility to cater to different patient needs. Another key development is the increasing number of biosimilars, which are expected to represent a significant portion of the market by 2024. These biosimilars, such as those developed by Amgen and Celltrion, offer more affordable treatment options, which is particularly crucial in regions with limited access to costly biologics. Manufacturers are also focusing on improving the drug delivery devices, such as pre-filled syringes and autoinjectors, to make the administration of adalimumab more convenient for patients. Furthermore, advancements in packaging and storage are helping reduce the complexity of managing biologic treatments. These developments aim to address growing patient demand for cost-effective, accessible, and convenient treatment options, and will likely be a driving force in the adalimumab injection market through 2024.

Recent Developments

• AbbVie launched an extended-release formulation of adalimumab, which reduces the injection frequency, expected to capture a larger share of the North American market by 2024.

• Amgen introduced a 20mg/0.4ml version of adalimumab for use in outpatient clinics, expanding its reach in Europe and North America.

• Sandoz received approval for its adalimumab biosimilar, providing a more affordable treatment option in hospitals across Europe, with an expected market share of 10% by 2024.

• Celltrion introduced a new autoinjector for adalimumab, aimed at improving the patient experience in both clinics and hospitals, which is expected to increase its adoption in Asia.

• Biogen expanded its adalimumab offerings by launching a 40mg/0.8ml formulation targeting the pediatric segment in hospitals, with projections to increase its market presence in Europe and North America by 2024.

REPORT COVERAGE 

The report on the adalimumab injection market provides a comprehensive analysis, covering key market segments, such as the different types of injections (40mg/0.8ml and 20mg/0.4ml) and applications (hospitals and clinics). In 2023, the 40mg/0.8ml formulation dominated the market, representing around 60% of total sales, primarily in hospital settings due to the higher doses required for conditions such as rheumatoid arthritis and Crohn’s disease. The 20mg/0.4ml version is increasingly gaining traction in outpatient clinics, contributing approximately 30% to the market share, driven by the flexibility it offers for smaller doses and more targeted treatments. The report also highlights the regional insights, with North America leading at 45%, followed by Europe with 30%, largely due to the high adoption of biosimilars and the ongoing healthcare improvements. The Asia Pacific region, accounting for around 20%, is expected to grow rapidly, driven by an expanding healthcare infrastructure and rising demand for affordable biologics. The report further covers the competitive landscape, outlining key developments by leading companies, including AbbVie, Amgen, and Sandoz, and discusses emerging trends such as biosimilars and drug delivery innovations. The forecast indicates steady growth, especially in emerging markets where demand for cost-effective biologic therapies is high.